Key facts
- 111Skin’s last known valuation is $120.7M (Jan 2025).
- It has raised $15.7M; the latest was PE Growth/Expansion ($7.4M) in Jan 2025.
- Notable investors include SKKY Partners, Vaultier7.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for 111Skin
- ·The full record, as it builds
Funding rounds
No funding rounds for 111Skin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 111Skin
Manufacturer of luxury skincare products and treatments intended to improve skin health and appearance. The company offers serums, cleansers, night creams, retinol patches, moisturizers, masks, and sunscreens to stimulate the production of intracellular antioxidants, as well as offers skincare treatments such as facials, spa, plastic surgery, and heat therapy, thereby helping its customers optimize skin both pre-and post-surgery.
- Sector
- Consumer Products and Services (B2C)
- HQ
- London, United Kingdom
- Founded
- 2012
- Employees
- 161
- Website
- 111skin.com/
- Ownership
- Privately Held (backing)
111Skin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 111Skin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 111Skin in its N-PORT filings yet. We sweep new filings monthly.